Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Tornier plans $205 Million IPO: Dutch orthopedic device maker Tornier seeks to raise up to $205 million in an initial public offering for debt repayment and "general corporate purposes," according to a June 7 filing with the Securities and Exchange Commission. Tornier, founded 70 years ago in France and acquired in 2006 by an investor group led by Warburg Pincus, focuses primarily on extremity joint treatments and claims the second largest worldwide market share for shoulder joint replacement products and the number one position in the U.S. market for foot and ankle joint replacements. Competitors include Johnson & Johnson/DePuy, Zimmer, Stryker, Wright Medical, Arthrex and ArthroCare. Tornier generated revenue of $201.5 million in 2009, up 13.6% from the prior year, with 57% of sales generated in the U.S. The firm had a net loss of $55.7 million for the year compared to a loss of $36.8 million in the prior year. Tornier stock would trade under the Nasdaq symbol "TRNX." Underwriters for the IPO include Merrill Lynch, J.P. Morgan, Piper Jaffray, Credit Suisse, Wells Fargo and William Blair & Company

You may also be interested in...



Financings In Brief

Tornier goes public

Novartis In Line For Ofatumumab MS Approval In June

Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.

Topics

UsernamePublicRestriction

Register

MT028997

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel